U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891183) titled 'Percutaneous Thermal Ablation in Lung Tumors' on Sept. 12, 2024.
Brief Summary: Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be gui...